Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology and other therapeutic areas. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities. We are dedicated to becoming a leading global pharmaceutical company.

In 2018, we acquired AstraZeneca's Seroquel and Seroquel XR in 51 countries and regions, accelerating the creation of a global commercial network. We also acquired the global rights to Bayer’s contraceptive patch product Apleek.

In 2019, we collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets. LY03004 entered the NDA phase in the U.S., and its manufacturing site passed the FDA Pre-Approval Inspection, making it the first innovative formulation developed by a Chinese company to enter the NDA phase in the U.S. Licensed by PharmaMar to develop Lurbinectedin in China, enabling Chinese patients to benefit from the new drug.

In 2021, we acquired Boan, accelerating development in the field of biopharmaceuticals. The once-daily Rivastigmine Transdermal Patch received market approval in China, to help improve safe treatment for patients with Alzheimer's disease.